Case Report: Disease progression of renal cell carcinoma containing a novel putative pathogenic KAT6A::NRG1 fusion on Ipilimumab- Nivolumab immunotherapy. A case study and review of the literature

Case Report: Disease progression of renal cell carcinoma containing a novel putative pathogenic KAT6A::NRG1 fusion on Ipilimumab- Nivolumab immunotherapy. A case study and review of the literature

Renal cell carcinoma still carries a poor prognosis despite therapeutic advancements. Detection of genetic mutations is vital in improving our understanding of this disease as well as potential role in targeted therapy. Here we present a case of a 49 year old man with an aggressive renal cell carcin...

Full description

Bibliographic Details
Main Authors: Almas Dawood, Suzanne MacMahon, My-Anh Tran Dang, Maxine G. B. Tran, Axel Bex, Ekaterini Boleti, Soha El Sheikh
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Oncology
Subjects:
renal cell carcinoma
Nrg1
KAT6A
fusion
mutation
immunotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1111706/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1111706/full

Similar Items